A group of Acredit members, led by Dr Sebastian Meltzer has published a new paper outlining that the higher the level of serum CD40 (sCD40) in the bloodstream, the shorter the time is to development of liver metastasis in rectal cancer patients.
These results, which included total 392 patients from 4 separate cohorts, point toward a possible use for sCD40 as a biomarker of risk of disease progression, but its presence may also indicate potential risk when using immunotherapy. Since sCD40 is related to inflammatory processes within the body, the finding that it is elevated within the blood of rectal cancer patients who go on to develop liver metastases may point to a role for measurement of the protein in the cancer care pathway. A high level of CD40 may be pointing toward immune exhaustion caused by the tumor, which may be helping enable metastasis. An additional recommendation is that the sCD40 level be measured before any experimental treatment with anti-CD40 agonistic antibodies is begun.
Co-authoring the paper are Acredit members Annette Torgunrud and Kjersti Flatmark (TCT), Hanna Abrahamsson, Kine Mari Bakke, Paula Anna Bousquet, Christin Johansen, and Anne Hansen Ree (CMOR), Anne Negård (GastroRad), Kathrine Røe Redalen (NTNU), Svein Dueland (Clinical and Translational Cancer Research group).
You can read Sebastian’s new paper here.